Scarica l'app Stockscreener
17.69
5.99%
1.00
Pre-mercato:
17.40
-0.29
-1.64%
Procept Biorobotics Corp Borsa (PRCT) Ultime notizie
PROCEPT BIOROBOTICS CORPORATION (PRCT) INVESTOR ALERT Investors With Large Losses in PROCEPT BioRobotics Corporation Should Contact Bernstein Liebhard LLP To Discuss Their Rights - Supply Chain Digital
PRCT Investors Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit - PR Newswire
INVESTOR ALERT: Securities Class Action Filed Against PROCEPT BioRobotics Corporation – Investors Encouraged to Contact Kirby McInerney LLP - Business Wire
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - marketscreener.com
Law Offices of Howard G. Smith Encourages PROCEPT BioRobotics Corporation (PRCT) Shareholders To Inquire About Securities Fraud Class Action - WBOC TV
Rosen Law Firm Urges PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Stockholders to Contact the Firm for Information About Their Rights - Business Wire
Notice to Long-Term Shareholders of Cogent Communications - GlobeNewswire
Notice to Long-Term Shareholders of Cogent Communications Holdings, Inc. (NASDAQ: CCOI); EquipmentShare.com, Inc. (NASDAQ: EQPT); Photronics, Inc. (NASDAQ: PLAB); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire Inc.
Class action lawsuit filed against PROCEPT BioR... - Pluang
PROCEPT BIOROBOTICS CORPORATION (PRCT) INVESTOR ALERT - GlobeNewswire
Procept Biorobotics Corp (PRCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Procept BioRobotics faces class action lawsuit over inflated sales and undisclosed inventory issues. - Pluang
PRCT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against PROCEPT BioRobotics Corporation and Announces Opportunity for Investors with Substantial Losses to Lead the Procept Class Action Lawsuit - PR Newswire
INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Intuit Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Class action lawsuit alleges PROCEPT BioRobotics inflated revenue via aggressive discounting. - Pluang
Procept BioRobotics: Filling Robots Slower Than Placing Them (NASDAQ:PRCT) - Seeking Alpha
Procept Biorobotics Corp (PRCT) Cash Flow - TradingKey
PRCT|Procept Biorobotics Corp|Price:17.700|Chg%:+1.010 - TradingKey
Procept Biorobotics Corp (PRCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PRCT Investors Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit with the Schall Law Firm - The Daily Tribune News
Procept Biorobotics Corp (PRCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PRCT|Procept Biorobotics Corp|Price:17.250|Chg%:+0.560 - TradingKey
Procept Biorobotics Corp. (PRCT) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Procept Biorobotics Corp. (PRCT) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Procept Biorobotics Corp (PRCT) Income Statement - TradingKey
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors Who Suffered Losses May Be Eligible to Participate in Securities Class Action; Contact Robbins LLP for Information About Recovering Your Losses - The AI Journal
PRCT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files - GlobeNewswire
PRCT|Procept Biorobotics Corp|Price:16.690|Chg%:-0.860 - TradingKey
Procept Biorobotics stock hits 52-week low at $17.95 By Investing.com - Investing.com South Africa
Procept Biorobotics stock hits 52-week low at $17.95 - Investing.com
PROCEPT BioRobotics Corporation (PRCT): Investor Outlook on a Potential 52% Upside in the Healthcare Sector - DirectorsTalk Interviews
Analysts’ Opinions Are Mixed on These Healthcare Stocks: TG Therapeutics (TGTX), Protagonist Therapeutics (PTGX) and PROCEPT BioRobotics (PRCT) - The Globe and Mail
PROCEPT BioRobotics (PRCT) Gains On Coverage And Trial Progress, Is The Stock Still Cheap? - Sahm
Mobia Medical (MOBI) names ex-PROCEPT CEO Reza Zadno as director - Stock Titan
Procept Biorobotics Corp stock hits 52-week low at 19.2 USD - Investing.com Nigeria
PROCEPT BioRobotics to report Q2 2026 results on August 4 - scanx.trade
Procept Biorobotics Corp stock hits 52-week low at 19.2 USD By Investing.com - Investing.com South Africa
PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026 - The Manila Times
PROCEPT BioRobotics to Report Second Quarter 2026 Financial Results on August 4th, 2026 - Moomoo
PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20 - Stocktwits
Procept BioRobotics shares slide after Leerink downgrade cites rising competitive risks - MSN
Pooja Sharma Net Worth (2026) - GuruFocus
Truist Financial Sticks to Its Hold Rating for PROCEPT BioRobotics (PRCT) - The Globe and Mail
PROCEPT BioRobotics stock stays guided by procedure demand - AD HOC NEWS
Truist Downgrades PROCEPT BioRobotics to Hold From Buy, Lowers Price Target to $25 From $30 - marketscreener.com
PRCTProcept BioRobotics Corp Dividends - Finviz
Truist cuts Procept BioRobotics stock rating on reimbursement concerns By Investing.com - Investing.com Nigeria
Truist cuts Procept BioRobotics stock rating on reimbursement concerns - Investing.com
Truist Securities downgraded the stock rating of PROCEPT BioRobotics Corp from "Buy" to "Hold" - Bitget
PROCEPT BioRobotics Jumps 3.94%: Key Levels for PRCT StockEarly Entry Signals - dars.gov.et
PROCEPT BioRobotics (PRCT) Is Up 7.2% After WATER IV Milestones Spotlight Aquablation’s Oncology Potential – Has The Bull Case Changed? - simplywall.st
Evercore Initiates PROCEPT BioRobotics (PRCT) At “Outperform,” Cites Aquablation Growth Potential - Insider Monkey
Price to book forward of PROCEPT BioRobotics Corporation – NASDAQ:PRCT - TradingView
Price to sales forward of PROCEPT BioRobotics Corporation – NASDAQ:PRCT - TradingView
Enterprise value to EBITDA forward of PROCEPT BioRobotics Corporation – NASDAQ:PRCT - TradingView
0.79%
4.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):